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Abstract 
Background: Cardiovascular disease is a leading cause of death among kidney transplant recipients. Metabolic 
syndrome increases the risk for cardiovascular events and decreases graft survival. Lately, guidelines for management 
of the metabolic syndrome, primarily hypertension, diabetes mellitus (DM) and hypercholesterolemia have dramati‑
cally changed in an attempt to decrease cardiovascular risks among kidney transplant recipients. In the present study 
we examined whether these guideline changes had impact on our management of post‑transplantation patients and 
the subsequent treatment outcomes for these diseases.
Methods: Data were obtained from kidney transplant clinic files from two follow‑up (FU) periods—between 
1994–1997 and between 2008–2011. Demographic data, monitoring and screening frequency for cardiovascular risk 
factors, immunosuppression regimen, treatment for hypertension, diabetes and hyperlipidemia, treatment outcomes 
and graft function changes were compared between the two follow‑up periods.
Results: There was a significant increase in the percentage of patients undergoing transplantation due to renal fail‑
ure secondary to diabetes and/or hypertension. Patient monitoring and screening during the second FU period were 
less frequent, but more targeted, reflecting changes in clinic routines. Blood pressure was better controlled in the 
second FU period (p < 0.01), as was hypercholesterolemia (p < 0.001). High fasting glucose levels were more preva‑
lent among patients in the second group (p < 0.005), although more patients received treatment for DM (p < 0.001). 
Significantly, fewer patients experienced deterioration of kidney functions during the second FU period (p < 0.001).
Conclusions: We found that guideline changes had impact on clinical practice, which translated to better control of 
the metabolic syndrome. DM control is challenging. Overall, stability of kidney function improved.
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Background
For kidney transplanted patients, graft failure is defined 
either as a need for a new renal replacement therapy or 
as patient’s death. Nowadays, about 50 % of graft losses 
are due to recipient’s death, a major cause for that being 
cardiovascular disease (CVD) [1, 2].
Many of the risk factors for CVD are included in the 
metabolic syndrome, which was first described as a 
combination of central obesity, dyslipidemia, hyperten-
sion and fasting hyperglycemia [3]. It has been shown 
that presence of metabolic syndrome in post-trans-
plantation patients increases the risk of major adverse 
cardiovascular events [4, 5]. In addition, these patients 
have lower graft survival [6] and a higher rate of chronic 
transplant dysfunction [7, 8]. The defining criteria most 
widely accepted today in post-transplantation patients 
is the one proposed by the International Diabetes Fed-
eration [9, 10]. Aside from traditional risk factors for 
CVD, transplant-associated risk factors such as various 
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immunosuppressive medications, chronic renal dysfunc-
tion and anemia are also acknowledged [11].
Understanding the importance of a balanced metabolic 
state for the general population has led to wide screening 
tests as well as early and aggressive interventions.
During the mid-90’s formal guidelines were not as 
common as they have become in the last 2 decades, more 
so in special populations such as kidney transplant recip-
ients [12]. Instead, there were recommended treatment 
targets that were accepted as common practice. ‘Kidney 
Disease—Improving Global Outcomes’ (KDIGO) was 
established in 2003 and has since published guidelines for 
management of patients with kidney diseases. The 2009 
KDIGO guidelines provide recommendations for the 
management of kidney transplant recipients, including 
screening and treatment goals [13].
Few large-scale studies have looked at the kidney trans-
plant recipients population, and though most suggested 
significant benefit in treating hyperlipidemia, diabetes 
(DM) and hypertension (HTN), evidence levels are not as 
strong as for the general population [14]. Encouragingly, 
early reports describing reduced incidence of cardiovas-
cular deaths in transplanted patients recently appeared, 
and suggest improvement in management of risk factors 
[15]. Unfortunately, treatment is still believed to be sub-
optimal [16, 17].
Here we aimed to elucidate the impact of changes in 
guidelines on our clinical management of post-transplan-
tation patients, and to test if improvement in controlling 
the metabolic syndrome evolved as reflected by patients’ 
blood pressure, fasting glucose levels, serum cholesterol 
and weights. We therefore compared patient’s monitor-
ing frequency, treatments and treatment outcomes and 
graft function from 2 different periods representing 
patients treated under two different follow-up guide-
lines: 1994–1997 and 2008–2011. Indeed, we found that 
patient monitoring has changed markedly between the 
two periods, more patients achieved treatments goals, 




Data were obtained from files of the out-patient clinic 
for the follow-up (FU) of kidney transplant recipients at 
Hadassah Hebrew University Medical center from two 
time periods: 1994–1997 and 2008–2011. All patients 
who were under observation for the full time-period (i.e. 
had visits at least once a year through one of the study 
periods) were included. Demographic data, transplant 
specifics, immunosuppressive medications, patient’s 
weights, prevalence of screening/monitoring tests 
for metabolic syndrome, treatments for the different 
cardiovascular risk factors and the last test results were 
recorded at the end of the relevant FU period. As no 
data was available regarding patients’ height we were not 
able to consider BMI. Data regarding ESRD etiology was 
based on the diagnosis as recorded in patient file.
The outcomes examined were glucose level, choles-
terol levels and blood pressure measurements as indica-
tive for control of the metabolic syndrome diseases. 
We also examined changes in serum creatinine during 
the FU period as a representation of kidney function. 
The incidence of new onset diabetes mellitus was also 
recorded. Glucose levels, cholesterol levels and blood 
pressure measurements were assessed as categorical val-
ues, in order to evaluate adherence to guidelines. As only 
patients under observation for the whole follow up time 
in each period were included, no graft survival could be 
calculated.
With the ethic committee approval no informed con-
sent was asked, as data were analyzed anonymously.
Statistical analysis
In order to test the association between two categori-
cal variables, the χ2 test and the Fisher’s exact test 
were applied. The comparison of quantitative variables 
between two independent groups was carried out using 
the t test or the non-parametric Mann–Whitney test 
when the data was not normally distributed. The logis-
tic multivariate model was applied (using the stepwise 
forward method), to simultaneously assess the effect 
of several variables on a dependent dichotomous out-
come variable. We also conducted a two-pass analysis 
(first considering baseline variables excluding FU period 
for selection into the logistic multivariable model as 
detailed in each section, and then testing FU period as 
an additional variable), receiving similar results to those 
achieved with the stepwise forward method. The mul-
tivariate linear regression model using the stepwise 
method was applied to quantitative dependent variables. 
All tests were two tailed and a p-value of 0.05 or less was 
considered statistically significant.
The following data were missing from patient records—
weight was unavailable for 44 patients (15 and 29 in 
groups I and II respectively), pre-transplant DM was 
unavailable for 4 patients  (3 and 1 in groups I and II 
respectively), last glucose was unavailable for 1 patient 
(from group I), last total cholesterol was unavailable for 
21 patients (1 and 20 in groups I and II respectively), 
last LDL was unavailable for 60 patients (40 and 20 in 
groups I and II respectively), last TG was unavailable for 
42 patients (24 and 18 in groups I and II respectively), 
last creatinine (and delta-creatinine) was unavailable for 
6 patients (all in group I). Only available data was used 
for statistical analysis.
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ESRD etiology was not clear for 41 patients (12 and 29 
in groups I and II respectively) as they presented with 
ESRD. They are included in others (see Table 1) as none 
of them had DM, HTN or familial disease.
Results
Patient characteristics
312 patient files met the criteria for inclusion in the study, 
74 in the first FU period and 238 in the second. Demo-
graphic and clinical characteristics are displayed in Table 1. 
Several significant differences between the two groups can 
be seen. Group II patients are older, with the mean age 47 
compared with 43 in group I, in accordance with world-
wide tendency to accept elderly patients to transplantation 
programs [1, 18, 19]. More patients in group II received 
kidneys from living donors (70  % compared to 50  % in 
group I). Additionally, etiology of ESRD differed signifi-
cantly between the groups, as polycystic diseases, diabetic 
and hypertensive nephropathies are more prevalent in 
group II, while glomerular diseases were more frequent in 
group I, well representing the changes in ESRD etiology [1].
Patients in group II weighed more (78 kg compared to 
72, p = 0.01). The prevalence of pre-transplant DM was 
significantly higher in group II (16.9 % compared 2.8 %, 
p  =  0.002), in accordance with the older age as men-
tioned of the recipients. Notably, serum creatinine levels 
at the beginning of the FU period were similar between 
the groups.
Table 1 Patient characteristics
ADPKD adult polycystic kidney disease, DM diabetes mellitus, HTN hypertension, FU follow up
a Pearson Chi square
b Fisher’s exact test
c T-test
1994–1997 2008–2011 p value
Number of patients 74 238
Sex 0.489a
 Male 66.20 % 61.80 %
 Female 33.80 % 38.20 %
ESRD etiology <0.005b
 APCKD 4.84 % 12.44 %
 Familial 11.29 % 15.79 %
 Glomerular disease 53.23 % 37.32 %
 DM 3.23 % 12.44 %
 HTN 0.00 % 5.26 %
 Other 27.42 % 16.75 %
Creatinine at beginning of FU period (μmol/l) (mean) 134 128 0.314c
Weight at beginning of FU period (kg) (mean) 72.3 78 0.01c
Pre‑transplant DM 2.8 % 16.9 % 0.002a
Cyclosporine treatment 90.5 % 29.0 % <0.001a
Last cyclosporine level (ng/mL) (mean) 139.3 63.3 <0.0001c
Tacrolimus treatment 0.0 % 60.9 % <0.001a
Last tacrolimus level (ng/mL) (mean) – 5.5
Place of transplant <0.001a
 Israel 80.0 % 47.8 %
 USA/Europe 6.7 % 11.4 %
 Others 13.3 % 40.8 %
Donor living/deceased 0.002a
 Deceased 50.8 % 29.6 %
 Living 49.2 % 70.4 %
Donor related 31.0 % 29.9 % 0.868a
Age at beginning of FU (mean) 43.15 ± 11.3 49.69 ± 13.6 0.001c
Years on dialysis (mean) 4.13 ± 4.9 2.88 ± 3.5 0.076c
Age at transplantation (mean) 38.57 ± 11.8 42.29 ± 14.4 0.026c
Years from transplantation (mean) 4.84 ± 3.8 7.15 ± 5.0 0.001c
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Tacrolimus was not used in the earlier time period, 
while 61  % of patients in group II received this drug. 
Accordingly, cyclosporine use decreased drastically. Fur-
thermore, cyclosporine mean blood levels were lower in 
the second group.
Patient monitoring
As seen in Fig.  1a, frequencies of blood pressure meas-
uring and lipid profile testing were significantly higher 
during the first study period. However, as blood pres-
sure (BP) is measured at every clinic visit, number of BP 
measurements directly represents the number of clinic 
visits. Patients in group I had more clinic visits, hence 
more BP measurements.
24-hour BP monitoring was more common in group 
II, though not statistically significant. During 2008–2011 
only 8.4 % of the patients underwent the test, indicating it 
has not yet become standard practice.
Lipid profile measurements were also more frequent in 
group I. We suspect that this difference is a result from 
a change in clinic practices, since in the second study 
period lipid measurements were ordered actively by the 
physician while in the first period they were done rou-
tinely at every clinic visit.
We were not able to compare diabetes monitoring and 
screening frequency. Data regarding fasting status at glu-
cose measurement during the second study period were 
missing, and HbA1C measurements were not available 
during the early period. Patients in group II had a mean 
of 1.3 measurements of HbA1C during the follow-up 
period. Patients already being treated for diabetes had 
a mean of 2.85 tests compared with 0.46 in patients not 
treated (Fig. 1b), indicating the test is used for monitor-
ing treatment efficiency rather than screening purposes.
Patients in group II had more PTH and DEXA meas-
urements per 4 years of follow-up.
Treatment outcomes
Diabetes mellitus
The targets of DM treatment are the same for kidney 
transplant recipients as for all diabetic patients, and suffi-
ciently intensive treatment should be given to maintain a 
HbA1C lower than 7.0–7.5 % [13], even if this means the 
permanent use of insulin. The recommended target was 
similar during the first study period [20].
The incidence of new-onset DM after transplant 
(NODAT) was higher in group II (14.7  % compared to 
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Fig. 1 Patient monitoring frequency, treatment and outcome. a Average number of measurements per patient during 4 years of FU. *p < 0.05; PTH 
para‑thyroid hormone, DEXA dual‑energy X‑ray absorptiometry, BP blood pressure. b Number of HbA1C measurements during the second period, 
comparison between patients treated for DM and patients that are not. (p < 0.001). c Last fasting glucose (p < 0.005). d DM treatment status in 
patients with last fasting Glucose >5.5 (p < 0.001). e Last fasting glucose in patients not treated for DM (p = 0.634)
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of patients receiving tacrolimus and the older age of this 
group.
Since HbA1C measurements were not available in the 
early period, we compared DM management between 
the patient groups by fasting glucose measurements. 
Glucose levels were assessed as a categorical variable, in 
order to differentiate controlled vs. uncontrolled diabe-
tes (controlled ≤7 mmol/L, uncontrolled >7 mmol/L). In 
group I more patients had a fasting glucose <7  mmol/L 
(e.g. as recommended) than in group II (Fig.  1c). Fac-
tors associated in univariable analysis with a significantly 
greater likelihood of having glucose levels >7  mmol/L 
were ESRD etiology (with diabetic nephropathy, APCKD 
and hypertensive nephropathy increasing this likelihood, 
p < 0.001), treatment with tacrolimus (p = 0.03), higher 
weight (p < 0.001) and older age at beginning of follow-
up (as a continuous variable, p < 0.001). Treatment with 
cyclosporine decreased this likelihood when compared to 
patients not treated with cyclosporine (p = 0.002). Using 
multivariate logistic regression model with the stepwise 
forward method, only ESRD etiology (p = 0.009, highest 
odds ratio for the diabetic nephropathy relative to famil-
ial with OR  =  6.9) and higher weight (p  =  0.027 with 
OR = 1.024) remained statistically significant. Testing FU 
period as an additional variable did not affect the results. 
Receiving treatment for DM was not included as a varia-
ble as when we tested that it reflected patients diagnosed 
as having DM (who naturally have higher fasting glucose 
levels) rather than impacting results. In conclusion, the 
data indicate that patients in the second FU period had a 
higher frequency of NODAT and higher fasting glucose 
levels, reflecting the higher percentage of patient under-
going transplantation because of DM and the more obese 
patients in the second time period.
Of patients in group II who had HbA1C measurements, 
46.2 % had HbA1C >7 %. As HbA1C was tested primar-
ily for monitoring pre-diagnosed diabetic patients, higher 
values were expected.
More patients with high fasting glucose levels were 
treated with medications through 2008-2011 than dur-
ing the earlier period (Fig. 1d). Still, success of DM con-
trol was lower in group II patients, maybe reflecting the 
higher percentage of patients undergoing transplanta-
tion because of DM. When comparing glucose levels of 
patients not treated for diabetes, no significant difference 
was found between the two FU periods (Fig. 1e).
Blood pressure
During the late 90’s, BP target was 140/90 [21], but 
adherence to the target was less strict. In addition, the 
emphasis was primarily on diastolic blood pressure, and 
treatment for isolated systolic hypertension was rec-
ommended only when above 160  mmHg [21]. KDIGO 
guidelines recommend target blood-pressure in kidney 
recipients of <130 mmHg systolic and <80 mmHg dias-
tolic [13]. Blood pressure was assessed as a categorical 
variable, in order to differentiate controlled vs. uncon-
trolled hypertension (controlled ≤130/80 mmHg, uncon-
trolled >130/80  mmHg). Both systolic and diastolic BP 
were better controlled in group II (Fig.  2a, b). Factors 
associated in univariable analysis with higher systolic 
BP were ESRD etiology (with hypertensive nephropathy, 
glomerular disease and diabetic nephropathy APCKD 
increasing likelihood for higher systolic BP, p  =  0.03), 
treatment with cyclosporine (p =  0.007), higher weight 
(p = 0.003), deterioration of kidney function (reflected by 
increase in creatinine as a continuous variable, p = 0.005) 
and older age at beginning of follow-up (as a continu-
ous variable, p = 0.046). Multivariate logistic regression 
model using the stepwise forward method indicated only 
age at beginning of follow-up (p = 0.01 with OR = 1.03 
per year) and increase in creatinine (p  =  0.004 with 
OR = 1.006) as statistically significant. As patients in the 
second period were older, the age could not account for 
the better blood pressure control found in the second 
group. Adding treatment or no treatment for blood pres-
sure as a variable in the multivariate analysis indicated a 
good correlation between having hypertension and being 
treated with antihypertensive drugs, but not with hyper-
tension control.
Of patients with last systolic BP >140, in group II 42.8 % 
were treated with 3 or more anti-hypertensive medica-
tions, compared to no such treatment in group I (Fig. 2c). 
Of note, only 13.5  % of group I patients received ACEi 
or ARB, with an increase to 61.8 % of treated patients in 
group II, consistent with the increasing use of these drugs 
in other renal diseases. These changes might account for 
the better blood pressure control, however not enough 
patients in each group were available for such analysis.
Hyperlipidemia
KDIGO guidelines recommend consideration of pharma-
cologic treatment for hypercholesterolemia at LDL above 
100 mg/dL or fasting triglycerides >500 mg/dL [13]. Pre-
vious recommendations for target lipid levels were LDL 
<130 mg/dL or total cholesterol <200 mg/dL [22].
Due to the scarcity of LDL measurements in the earlier 
period we compared total cholesterol levels as well. Cho-
lesterol levels were assessed as a categorical variable, in 
order to differentiate controlled vs. uncontrolled hyper-
cholesterolemia (controlled ≤193  mg/dL, uncontrolled 
>193  mg/dL). Total cholesterol was better controlled at 
the second period (Fig. 2d). Factors associated in univari-
able analysis with higher cholesterol levels were ESRD 
etiology (with glomerular disease, familial nephropa-
thies and diabetic nephropathy increasing said likelihood, 
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p  =  0.013), treatment with cyclosporine (p  <  0.001), 
fewer years since transplant (p  =  0.05) and surpris-
ingly younger age at beginning of follow-up (p = 0.004). 
Treatment with tacrolimus decreased this likelihood 
(p  <  0.001). However, when multivariate logistic regres-
sion model was applied using the stepwise forward 
method, only follow-up period remained statistically sig-
nificant (p < 0.001), expressing the multitude of changes 
between the time periods and maybe the fact that shorter 
time of fasting was requested from patients before taking 
blood for cholesterol levels. Treatment was more com-
mon in the second period (Fig. 2e). Similar results were 
found for LDL levels (Fig. 2f ).
58.2 % of patients in group II had TG levels under 150 
compared to 40 % in group I (p < 0.02). Levels above 500 
were rare (only 1 patient in group I and none in group II).
Adherence to guidelines
Table  2 compares the overall adherence to guidelines 
between the two patient groups, based on relevant com-
mon practice/guideline during that period. As one can 
see, a significant increase in treatment targets achieve-
ment was observed for diastolic blood pressure, total 
cholesterol and LDL levels. No difference was found in 
systolic blood pressure control according to the relevant 
recommendation (<140  mmHg for the 1st period and 
then <130 mmHg for the 2nd). During the second period, 
fewer patients achieved serum glucose target levels then 
during the first period. This can be related to the higher 
average age and the higher prevalence of DM among 
patients transplanted in the second period.
Kidney functions
An important and encouraging finding is the difference 
noted between the groups regarding stability in kidney 
function. Serum creatinine levels were measured at the 
beginning and end of the FU period and delta-creati-
nine (creatinine level at the end of FU minus creatinine 
level at the beginning of FU) was calculated. Changes 
in kidney function were defined as follows: improve-
ment =  decrease in creatinine >50 μmol/l or return to 
normal range, deterioration  =  increase in creatinine 
50–100  μmol/l, significant deterioration  =  increase in 
creatinine >100 μmol/L. The data show that only 5.1   % 
of patients in group II experienced a deterioration in 
kidney function during the follow-up period compared 
to 29.8  % in group I (Table 3). Factors associated in uni-
variable analysis with higher delta-creatinine (reflecting 
deterioration in kidney function) were treatment with 
cyclosporine (p < 0.001), higher BP (systolic & diastolic, 
p = 0.005 and p = 0.01 respectively), higher cholesterol 
levels (p < 0.001). Treatment with tacrolimus was associ-
ated with lower delta-creatinine (p < 0.001). Weak asso-
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Fig. 2 HTN and hypercholesterolemia treatment outcome. a Last systolic BP (p < 0.01). b Last diastolic BP (p < 0.001). c Number of medications for 
treatment of HTN in patients with last systolic BP >140 (p < 0.03).  d Last total cholesterol (mg/dL) (p < 0.001). e Percentage of patients receiving 
treatment for hypercholesterolemia among those with total cholesterol >193 (p < 0.0001). f Last LDL (mg/dL) (p < 0.001)
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age at transplant (p  =  0.04) and years since transplant 
(p  =  0.03), all associated with higher delta creatinine. 
Notably, no association was found between change in 
creatinine and ESRD etiology. When the multivariate 
linear regression model using the stepwise method was 
applied, only FU period remained significant (p < 0.001) 
suggesting relation between some of the factors men-
tioned above as the use of cyclosporine and higher blood 
pressure and higher levels of cholesterol. It also suggests 
that it is the combination of factors that results in the 
change
Discussion
In this study, we aimed to determine whether changes 
in guidelines for monitoring and treatment of CVD risk 
factors have been implemented in our clinic and whether 
treatment outcomes of these risk factors have improved. 
We therefore examined records from 2 different periods 
representing patients treated under two different follow-
up guidelines, and compared monitoring frequency and 
treatment outcomes.
The two patient groups differed in many aspects, in 
accordance with trends seen in the transplantation world 
during the last years. Changes in patient demograph-
ics as ESRD etiology and age, increase in the percentage 
of living donors, emergence of new immunosuppressive 
drugs, subsequent change in treatment protocols and 
heightened awareness for the metabolic syndrome, can 
have an impact on the metabolic syndrome itself, and on 
graft function and survival, and therefore were taken into 
account when analyzing treatment outcomes.
Our results show that patient monitoring has changed 
markedly between the two periods. While some tests 
were done more frequently during 1994–1997 due to 
automatic routines, during the second study period the 
clinic practices have become more methodical.
DM is now the most common cause of ESRD leading 
to transplantation [1], is prevalent in ESRD patients as 
co-morbidity, and is also one of the most important risk 
factor for post-transplantation CVD [23–25]. The lat-
ter is also true for NODAT [26, 27]. Up-to 30 % of post-
transplantation patients will develop glucose intolerance 
[28] that might lead to reduced survival and a higher inci-
dence of cardiovascular events [29]. Only low percent-
ages of patients in both periods were not treated for DM 
though treatment was indicated because of their fasting 
glucose and no difference was found between the two 
time periods. Fasting glucose levels and HbA1C were 
higher in patients from the second study period even 
though more patients received treatment for DM. This is 
mainly explained by higher mean age in group II, higher 
prevalence of DM as the etiology of ESRD, and the use 
of tacrolimus instead of cyclosporine in the second FU 
period.
Hypertension occurs in 60 to 80 % of renal transplant 
recipients, associated with an increased risk for chronic 
graft failure and CVD [30, 31]. Causes include donor 
characteristics, retained native kidneys, allograft dys-
function, immunosuppressive drugs and more [31, 32]. 
There is still no clearly preferred agent for treatment 
[10, 13, 31, 33, 34]. ACEi/ARB use was associated with a 
reduction in mortality though not with better graft sur-
vival [35].
We were pleased to see that BP improved dramatically 
between the two time periods. We believe this result 
from heightened physicians’ awareness and earlier and 
more aggressive treatment, as can be seen in the signifi-
cant increase in number of medications used.
Table 2 Overall adherence to guidelines
The percentage of patients achieving treatment goals during the two FU periods was compared. For each FU period the relevant treatment targets were used
FU follow up, LDL low density cholesterol
Number of patients achieving  
target levels—1994–1997
Number of patients achieving  
target levels—2008–2011
p value
Systolic blood pressure 75.7 % (<140 mmHg) 76.5 % (<130 mmHg) 0.888
Diastolic blood pressure 68 % (<90 mmHg) 79.8 % (<80 mmHg) 0.029
Fasting blood glucose (<7 mmol/L) 94.5 % 79.3 % 0.005
Total cholesterol (<193 mg/dL) 23.3 % 74.3 % <0.001
LDL 38 % (<130 mg/dL) 57.8 % (<100 mg/dL) 0.033
Table 3 Changes in kidney function
Improvement = decrease in creatinine >50 μmol/l or return to normal 
range, deterioration = increase in creatinine 50–100 μmol/l, significant 
deterioration = increase in creatinine >100 μmol/l (p < 0.001 for all parameter 
tested)




Significant deterioration 17.6 3.4
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Hyperlipidemia leads to increased risk of CVD after 
renal transplantation [36]. In the ALERT trial the risk of 
major adverse cardiac event was not significantly affected 
by fluvastatin treatment, however patients receiving flu-
vastatin exhibited lower rate of cardiac death and non-
fatal myocardial infarction [14]. The extension study, 
demonstrated a significantly reduced risk of major 
adverse cardiovascular events after 2 more years of FU 
[37]. We find highly significant lower cholesterol levels in 
the second study period compared to the first. Actually, 
the greatest difference in outcomes seen between the 2 
periods appears to be in the percentage of patients who 
achieved target total cholesterol levels.
The significant improvement in metabolic syndrome 
control between the groups results from evolution in 
patient treatment that occurred during the last two dec-
ades. It can be attributed to an increased awareness to 
monitoring and treatment of the metabolic syndrome 
components, but it might also be the consequence of 
other changes. Immunosuppressive drugs, among other 
factors, can contribute to the metabolic syndrome in 
transplant patients [23]. For example, hypertension 
prevalence increased after treatment with calcineurin 
inhibitors was introduced [31]. Cyclosporine, more than 
tacrolimus, is associated with hypertension and hyper-
lipidemia [38]. Cyclosporine use decreased in the sec-
ond FU period as well as mean cyclosporine blood levels. 
Also, patients awareness to healthy life style, including 
dietary habits could affect blood pressure and cholesterol 
levels, and this could not be evaluated.
Kidney function stability in the later follow-up period 
is probably multifactorial. It can be attributed, in part, to 
improvement in immunosuppressive regimen including 
the addition of tacrolimus. Another factor contributing 
to better graft survival might be an increased rate of liv-
ing donors. However, as graft survival nowadays is highly 
affected by cardiovascular morbidity and mortality of the 
recipients, we believe that some of the change for the bet-
ter in kidney function stability is related to a better con-
trol of the metabolic syndrome.
Since the study was conducted in one medical center 
there may be a selection bias. However, as the population 
in our clinic is diverse and includes many different sub-
populations, we expect this selection bias to be minimal. 
An additional limitation was the relatively small number 
of patients in the first time period, which might cause 
selection bias. The reason for a smaller group was partly 
because of lower total number of patients followed at the 
clinic at that time. Also, small number of patients were 
not included because they did not meet the inclusion 
criteria of a yearly visit through the whole period, some 
of them because they went back to dialysis. This might 
cause a bias decreasing the differences seen between the 
two groups regarding the kidney functions outcome, but 
also regarding the blood pressure. Also, the total per-
centages of patients having a metabolic syndrome could 
not be evaluated, as no data was available about patients’ 
height (thus preventing us from calculating the BMI) or 
central obesity. Missing data was not a significant prob-
lem for data related to kidney function, glucose levels 
and blood pressure therefore not considered as poten-
tial source for bias. Cholesterol levels were absent for 20 
out of 273 patients from the second period. As patients 
in this group had significantly much lower cholesterol 
levels, this could cause a bias by decreasing the improve-
ments we found in controlling cholesterol levels.
In conclusion, our results indicate that changes in 
guidelines for monitoring and treatment goals of the 
metabolic syndrome have had a great impact on manage-
ment of kidney transplant recipients. The majority of the 
patients meet the treatment goals as defined by KDIGO, 
even though there is still a significant number of patients 
who require further efforts to achieve better clinical out-
comes, especially regarding DM control. The significant 
improvement we saw in kidney function stability over 
time was most gratifying, as it demonstrates that overall, 
the various changes in management of renal transplant 
patients in the last decade, including among other things 
modification of immunosuprressive regiments and better 
control of blood pressure and cholesterol levels are asso-
ciated with improvement graft function.
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